IP Library Granted Patent US 10,617,763
Granted Patent B2
US 10,617,763 · App. 15/864,703 · Granted Apr 14, 2020

Compositions and methods for the treatment of presbyopia

Inventors: Gerald Horn (Deerfield, IL); Lee Nordan (Dana Point, CA)
Assignee: PRESBYOPIA THERAPIES, LLC
A61K47/40A61K9/0048A61K31/439A61K47/02A61K47/10A61K47/14A61K47/186A61K47/26A61K47/32A61K47/34A61K47/38A61P27/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,617,763
App. No.
15/864,703
Granted
Apr 14, 2020
Kind
B2
Abstract

The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine and a cryoprotectant. The compositions optionally contain a cycloplegic agent, a surfactant, a viscosity enhancer, an osmolarity modifier and a preservative.

Claims (5)

1. An ophthalmological composition for the treatment of presbyopia comprising a cryoprotectant selected from the group consisting of glucose, sucrose, trehalose, lactose, maltose, fructose, amyl alcohol, butanol, sec-butanol, t-butyl alcohol, n-butyl alcohol, isobutanol, methanol, isopropanol, propanol, cyclic amide, gentisic acid, colloidal silicon dioxide, polyvinyl alcohol, 2-methyl-2,4-pentanediol, cellobiose, gelatin, formamide and antifreeze protein 752 and an active agent consisting of aceclidine.

2. The composition of claim 1 , wherein the aceclidine is at a concentration from about 0.25% to about 2.5% w/v, wherein w/v denotes weight by total volume of the composition.

3. The composition of claim 1 , wherein the cryoprotectant is at a concentration from about 1% to about 10% w/v, wherein w/v denotes weight by total volume of the composition

4. A method of treating presbyopia comprising administering to a subject in need thereof the ophthalmological composition of claim 1 .

5. A method of treating irregular astigmatism, keratoconic ectasia, night vision halos/starbursts, night vision reduced contrast, and low myopia, or hyperopia, with or without astigmatism, comprising administering to a subject in need thereof the ophthalmological composition of claim 1 .

Assignments (4)
CHANGE OF NAME Recorded Apr 2, 2024
From: LENZ THERAPEUTICS, INC.
To: LENZ THERAPEUTICS OPERATIONS, INC.
Reel/Frame 066978/0082 →
CHANGE OF NAME Recorded Dec 15, 2022
From: PRESBYOPIA THERAPIES, INC.
To: LENZ THERAPEUTICS, INC.
Reel/Frame 062138/0206 →
CHANGE OF NAME Recorded Nov 9, 2020
From: PRESBYOPIA THERAPIES, LLC
To: PRESBYOPIA THERAPIES, INC.
Reel/Frame 054363/0516 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2020
From: HORN, GERALD; NORDAN, LEE
To: PRESBYOPIA THERAPIES, LLC
Reel/Frame 052849/0632 →
Continuity (10)
Continuation In Part 15235431 · Aug 12, 2016
Continuation In Part 15073089 · Mar 17, 2016
Continuation In Part 14742903 · Jun 18, 2015
Continuation In Part 14223639 · Mar 24, 2014
Provisional Application 61938438 · Feb 11, 2014
Provisional Application 61917620 · Dec 18, 2013
Provisional Application 61904510 · Nov 15, 2013
Provisional Application 61882998 · Sep 26, 2013
Provisional Application 61871215 · Aug 28, 2013
Related Publication 20180140708A1 · May 24, 2018
Cited By (3)
US 12,414,942 US 12,533,347 US 12,653,779